Literature DB >> 21360474

LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.

Rodney G Bowden1, Ronald L Wilson, A Alexander Beaujean.   

Abstract

BACKGROUND: Few studies have been conducted that make comparisons between traditional measures of cholesterol and cholesterol subfractions, and only one study has compared low-density lipoprotein cholesterol (LDL-C) particle number, LDL-C particle size and LDL-C among end-stage renal disease (ESRD) patients. The purpose of this study was to examine the relationships between cholesterol measures and differences in risk stratification when using ATP-III guidelines compared with cholesterol particle number and size in ESRD patients.
METHODS: ESRD patients (n=1,092) from clinics associated with the Central Texas Nephrology Associates were recruited to participate in this study.
RESULTS: LDL particle size categorized more patients at-risk when compared with LDL-C, non-HDL-C and triglycerides. Pearson correlation coefficients revealed a strong significant correlation between LDL-C and LDL particle number (r2=0.908, p=0.0001) and a significant correlation between LDL particle number and LDL particle size (r2=-0.290, p=0.0001). A significant but weak correlation existed between LDL-C and LDL particle size (r2=0.107, p=0.0001). A significant correlation existed between LDL particle number and triglycerides (r2=0.335, p=0.0001) and a significant inverse relationship between LDL particle size and triglycerides (r2=-0.500, p=0.0001).
CONCLUSIONS: Our study seems to suggest that using LDL particle size may help to identify those who would not be considered at-risk using LDL-C, non-HDL-C or triglycerides alone, and can be used as a further screening measure that may be more predictive of coronary heart disease outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360474      PMCID: PMC4313745          DOI: 10.5301/JN.2011.6376

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  19 in total

1.  [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol].

Authors:  Toshiyuki Hayashi; Tsutomu Hirano; Tomomi Shiobara; Toshiaki Suguro; Mitsuru Adachi
Journal:  Rinsho Byori       Date:  2006-06

2.  Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.

Authors:  Sekar Kathiresan; James D Otvos; Lisa M Sullivan; Michelle J Keyes; Ernst J Schaefer; Peter W F Wilson; Ralph B D'Agostino; Ramachandran S Vasan; Sander J Robins
Journal:  Circulation       Date:  2005-12-27       Impact factor: 29.690

Review 3.  Low-density lipoprotein reduction in high-risk patients: how low do you go?

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

4.  Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women.

Authors:  Samia Mora; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2009-05       Impact factor: 8.327

5.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  S S Soedamah-Muthu; Y-F Chang; J Otvos; R W Evans; T J Orchard
Journal:  Diabetologia       Date:  2003-05-13       Impact factor: 10.122

6.  Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.

Authors:  Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

7.  Lipoprotein particle distribution and size, insulin resistance, and metabolic syndrome in Alaska Eskimos: the GOCADAN study.

Authors:  Angela A Rivellese; Lidia Patti; David Kaufman; Jianhui Zhu; Giovanni Annuzzi; Olga Vaccaro; Sven O Ebbesson; Wm James Howard; Gabriele Riccardi; Barbara V Howard
Journal:  Atherosclerosis       Date:  2008-04-18       Impact factor: 5.162

8.  High-density lipoprotein particle size and concentration and coronary risk.

Authors:  Karim El Harchaoui; Benoit J Arsenault; Remco Franssen; Jean-Pierre Després; G Kees Hovingh; Erik S G Stroes; James D Otvos; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  Ann Intern Med       Date:  2009-01-20       Impact factor: 25.391

Review 9.  Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use.

Authors:  Samia Mora
Journal:  Circulation       Date:  2009-05-05       Impact factor: 29.690

10.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Authors:  John H Contois; Joseph P McConnell; Amar A Sethi; Gyorgy Csako; Sridevi Devaraj; Daniel M Hoefner; G Russell Warnick
Journal:  Clin Chem       Date:  2009-01-23       Impact factor: 8.327

View more
  4 in total

1.  Lipoprotein subfractions and particle size in end-stage renal disease.

Authors:  Peter A McCullough; Fawaz Al-Ejel; Robert C Maynard
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

2.  Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.

Authors:  Archna Bajaj; Dawei Xie; Esteban Cedillo-Couvert; Jeanne Charleston; Jing Chen; Rajat Deo; Harold I Feldman; Alan S Go; Jiang He; Edward Horwitz; Radhakrishna Kallem; Mahboob Rahman; Matthew R Weir; Amanda H Anderson; Daniel J Rader
Journal:  Am J Kidney Dis       Date:  2019-01-25       Impact factor: 8.860

3.  Proinflammatory and Hyperinsulinemic Dietary Patterns Are Associated With Specific Profiles of Biomarkers Predictive of Chronic Inflammation, Glucose-Insulin Dysregulation, and Dyslipidemia in Postmenopausal Women.

Authors:  Ni Shi; Desmond Aroke; Qi Jin; Dong Hoon Lee; Hisham Hussan; Xuehong Zhang; JoAnn E Manson; Erin S LeBlanc; Ana Barac; Chrisa Arcan; Steven K Clinton; Edward L Giovannucci; Fred K Tabung
Journal:  Front Nutr       Date:  2021-09-20

4.  Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients.

Authors:  Marcelino Bermudez-Lopez; Hector Perpiñan; Nuria Amigo; Eva Castro; Nuria Alonso; Didac Mauricio; Elvira Fernandez; Jose M Valdivielso
Journal:  Clin Kidney J       Date:  2021-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.